Tamiflu U.S. Labeling Adopts Japanese Warnings
This article was originally published in The Pink Sheet Daily
Executive Summary
Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.